Objectives To estimate Alirocumabś clinical and budget impact, compared with standard
lipid modifying therapy, for the private and social security health systems, covering> 50% of …

Background and aims ODYSSEY OLE (open-label extension; NCT01954394) included
patients diagnosed with heterozygous familial hypercholesterolemia (HeFH), receiving …

Introduction and objectives To analyze the cost-effectiveness ratio and budget impact of
treatment with evolocumab (PCSK9 inhibitor) for patients in secondary prevention in the …

Background Individuals with heterozygous familial hypercholesterolemia (heFH) have
higher levels of low-density lipoprotein cholesterol (LDL-C) and are predisposed to …

Background Inadequate control of cardiovascular (CV) risk is common in patients with
heterozygous familial hypercholesterolemia (HeFH), or in non-FH patients at high CV risk …

Background ODYSSEY OLE (NCT01954394) was an open-label extension (OLE) study for
patients with heterozygous familial hypercholesterolemia (HeFH) who had completed …

Purpose During the alirocumab open-label extension study ODYSSEY OLE (open-label
extension; NCT01954394), physicians could adjust alirocumab dosing for enrolled patients …

A real-world setting study of familial hypercholesterolemia (FH) patients who received
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in a specialized referral …

Abstract Background: In 2019, the European Atherosclerosis Society (EAS) published
updated guidelines, recommending even lower blood cholesterol targets than previously. In …

Aims To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous
familial hypercholesterolaemia (HeFH) and inadequate LDL-C control on maximally …